THU0212 REINVESTMENT OF BIOSIMILAR SAVINGS: WHAT ARE THE BEST OPTIONS?

M. Martin, R. Campbell, J. Jacob. Consulting, Syneos Health, London, UK

Background: Biosimilars are becoming available for many of the biologic compounds in rheumatoid arthritis (RA). Biosimilars provide similar benefit at a reduced cost, therefore generating potential savings to the health care system.

Objectives: To investigate whether it is most beneficial to reinvest biosimilar savings to treat additional RA patients or whether this same budget would be more beneficially spent on alternative treatments from a UK payer perspective.

Methods: We developed a model to first estimate the savings obtained from using biosimilars from a UK National Health Service (NHS) perspective. Then we identified five treatment alternatives, in addition to RA: melanoma, hepatitis C (HepC), multiple sclerosis (MS), Duchenne's disease (MD), and non-small cell lung cancer (NSCLC). These indications were considered because of their burden of illness, high cost but high efficacy treatments being available which are associated with investment pressures. The treatments selected were: ataluren (MD), natalizumab (MS), pembrolizumab (melanoma), crizotinib (NSCLC), sofosbuvir + ribavirin (HepC), and etanercept biosimilar. We estimated the health gain (expressed as QALYs) that could be obtained from treating the patients in the four indications of interest using the available savings to identify the most cost-effective way to spend the savings. Data on QALY gains were obtained from published sources, mostly HTA assessments.

Results: Based on a biologics expenditure of ~£430 million, we estimated that ~£5 million in savings would be generated over a 5 year period.

Based on the outcome of QALY maximisation, over a 5 year period, biosimilar savings in the UK are best spent on treatments in hepatitis C, followed by NSCLC and melanoma. Re-investment in an RA biosimilar only came in 5th place, before cystic fibrosis.

Conclusions: In a country like the UK, where patients have ready access to biologics, the savings from prescribing biosimilars can be better spent, if QALY maximisation is desired, on non-RA therapies where over a 5 year period more QALYs are generated. On the basis of the research, payers should consider the potential to reinvest biosimilar savings in disease areas with higher QALY yields.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6503

THU0213 ADHERENCE AND PERSISTENCE TO DISEASE MODIFYING ANTI RHEUMATIC DRUGS IN COLOMBIAN PATIENTS WITH RHEUMATOID ARTHRITIS

N. Pertuz-Charris¹, F.L. Ochoa-Jaramillo², D. Gil-Calderón¹, M.A. Alzate-Vinasco¹, V. Vélez-Marín¹, D. Hernández-Parra³, R. Pineda-Tamayo¹. ¹Rheumatology, Artmedica IPS; ²Public health group, CES University; ³Clinical research department, Artmedica IPS, Medellín, Colombia

Background: Adherence in the treatment of rheumatoid arthritis (RA) ranges 20% to 70% in worldwide population.¹ In Colombia there are no studies comparing adherence and persistence to conventional and biological treatment.

Objectives: To determine adherence and persistence and associated factors to the treatment of conventional disease-modifying anti-rheumatic drugs (cDMARD) and biological DMARD (bDMARD) in patients with RA under real world data.

Methods: We conducted an observational, analytical retrospective cohort study from January 2015 to December 2016. The study population was 552 RA patients older than 18 years who received any cDMARD treatment in monotherapy or combined with two or more cDMARD and bDMARD (Rituximab and Tofacitinib were excluded). Clinical information was obtained from electronic clinical records and Morisky-Green test was performed during the follow-up. Univariate analysis (proportions and medians), bivariate analysis [relative risk (RR)] and multivariate analysis (logistic regression and Kaplan-Meier survival curve) were developed.

Results: Eighty nine percent were women, the median age was 59 years, 50% have ≥12 years of duration of disease. Adherence for cDMARD was 61% and for bDMARD 56%. There was an association between adherence and high degree education level (adjusted RR=2.1; **CI: 1.09–4.14**) and non-adherence with clinical factors such as high disease activity (adjusted RR=0.41; **CI: 0.22–0.75**); in the cDMARD group the greatest persistence was leflunomide (mean: 631 days) followed by methotrexate (mean: 526 days) and in the bDMARD group was etanercept (mean 1577 days) and tocilizumab (mean 1064 days). Patients with social support had greater persistence in the treatment with cDMARD (adjusted HR=2.1; **CI: 1.11–4.28**).

Abstract THU0213 – Table 1. Sociodemographic, clinical and therapeutic characteristics in 552 Colombian patients with rheumatoid arthritis

Characteristics	n	(%)
Rheumatoid factor	415	81
ACPA	150	71

DAS-28	<2,6	267	49
	2,6–3,2	68	12
	3,2–4,9	129	23
	>5	88	16
cDMARD	Methotrexate	281	55
	Leflunomide	130	25
	Sulfasalazine	71	14
	Chloroquine	30	6
bDMARD	Tocilizumab	41	24
	Adalimumab	38	22
	Abatacept	32	19
	Etanercept	29	17
	Infliximab	14	8,2
	Golimumab	11	6,4
	Certolizumab	6	3,5

IQR: interquartile range, ACPA: anti-cyclic citrullinated protein/peptide antibodies

Abstract THU0213 – Figure 1. The median time of follow-up of the studied population was 822 days, IQR 429–727 days.

Conclusions: In real world data, education level and disease activity significantly impact adherence level in RA patients. Social support positively impacts the persistence of the treatment of RA patients, which suggest the implementation of care programs taking this aspect into consideration in order to improve outcomes.

REFERENCE:

- [1] De Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. *J Rheumatol* 2003;(1):44–54.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6091

THU0214 PREDICTIVE FACTORS FOR ACHIEVEMENT OF LOW DISEASE ACTIVITY AT 52 WEEKS ARE DIFFERENT BETWEEN YOUNG AND ELDERLY RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT

N. Takahashi, T. Kojima, S. Asai, N. Ishiguro, on behalf of the TBCR study group. Orthopaedic Surgery, Nagoya University Graduate School Of Medicine, Nagoya, Japan

Background: Japanese post-marketing survey (PMS) data demonstrated that the clinical efficacy of abatacept was similar between the young and elderly rheumatoid arthritis (RA) patients, while they have quite different characteristics including age, disease duration, and concomitant drugs. We hypothesised that the predictive factors for clinical outcomes of abatacept were different between the young and elderly patients.

Objectives: We studied the predictive factors for good clinical response of abatacept in the young and elderly patients, respectively, in this study.

Methods: Participants were consecutive 463 RA patients treated with abatacept and observed for longer than 52 weeks in the TBCR, a Japanese multicenter registry system for RA patients treated with biologics. Univariate and multivariate logistic regression analysis was used to study predictive factors for achievement

of low disease activity (LDA) at 52 weeks, separately in the young (<65 years, n=215) and the elderly (>65 years, n=248) group.

Results: Mean age was 55.3/74.0 years (young/elderly), disease duration was 10.2/12.8 years, DAS28-CRP was 4.34/4.40 at baseline, concomitant MTX was used in 55.4/37.1%, concomitant steroid was used in 51.0/49.6%, and proportion of bio-naïve was 49.3/63.3%. As shown in table 1, multivariate analysis revealed that no history of previous biologics and lower DAS28 score at baseline was the independent positive predictors in both young and elderly group. Interestingly, ACPA positivity was significant predictor only in the young group. The ACPA positive patients showed the significantly higher proportion of LDA achievement at 52 weeks, only in the young group (figure 1).

Conclusions: It has been reported that lower proportion of the elderly onset RA (EORA) patients has ACPA positivity, and some reports have previously demonstrated that the ACPA negative was negatively associated with good clinical outcomes of abatacept. Our current results suggested that the effect of ACPA positivity on the clinical results of abatacept treatment was different between ages. Abatacept would be a valuable treatment option in the ACPA negative elderly RA patients.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3382

Abstract THU0214 – Table 1. Logistic regression analysis to study predictive factors for LDA achievement at 52 weeks.

	Univariate		Multivariate	
	OR (95% CI)	p-value	OR (95% CI)	p-value
<65 years				
Male	0.944 (0.438–2.036)	0.884		
Disease duration, <10 years	1.454 (0.771–2.742)	0.248		
ACPA positive	3.044 (1.070–8.656)	0.037	4.544 (1.049–19.689)	0.043
No previous biological DMARDs	2.458 (1.336–4.524)	0.004	3.386 (1.119–10.244)	0.031
Concomitant MTX	1.879 (1.022–3.453)	0.042		
Concomitant PSL	0.693 (0.380–1.265)	0.232		
mHAQ, <0.5	2.756 (1.373–5.531)	0.004		
DAS28-CRP at baseline	0.631 (0.489–0.814)	<0.001	0.457 (0.260–0.803)	0.006
>65 years				
Male	1.205 (0.601–2.418)	0.599		
Disease duration, <10 years	2.154 (1.120–4.141)	0.021		
ACPA positive	0.697 (0.284–1.711)	0.431		
No previous biological DMARDs	3.040 (1.564–5.912)	0.001	3.678 (1.370–9.876)	0.010
Concomitant MTX	1.357 (0.746–2.467)	0.318		
Concomitant PSL	0.469 (0.256–0.857)	0.014		
mHAQ, <0.5	3.224 (1.670–6.224)	<0.001		
DAS28-CRP at baseline	0.571 (0.444–0.736)	<0.001	0.638 (0.433–0.942)	0.024

THU0215

EFFICACY OF SARILUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH AND WITHOUT PREVIOUS RESPONSE TO TOCILIZUMAB

P. Verschueren¹, P. Emery², H. van Hoogstraten³, Q. Dong³, E.K. Mangan⁴, A. den Broeder⁵. ¹Division of Rheumatology, University Hospital Leuven, Leuven, Belgium; ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; ³Sanofi Genzyme, Bridgewater, NJ, USA; ⁴Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA; ⁵Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands

Background: Sarilumab is an IL-6R inhibitor recently approved for the treatment of rheumatoid arthritis (RA). To help clinical decision making, we studied the response rate on open-label sarilumab treatment in patients previously treated with tocilizumab, the other IL-6R inhibitor approved for RA. In the ASCERTAIN trial (NCT01768572), patients were randomised 1:1:2 to 24 weeks of sarilumab 150 mg sc every 2 weeks (q2w; n=49), sarilumab 200 mg sc q2w (n=51), or tocilizumab 4 mg/kg iv q4w (n=102) increased to 8 mg/kg at investigator's discretion if clinically indicated as per the US label; each added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) background therapy. Patients who completed ASCERTAIN were eligible to enrol in an open-label extension study of sarilumab 200 mg sc q2w (EXTEND, NCT01146652), with csDMARDs as specified in the previous study.

Objectives: To examine outcomes for patients who switched from tocilizumab in ASCERTAIN to open-label sarilumab in EXTEND.

Methods: In this post-hoc analysis, patients were recorded as responders or non-responders at the end of ASCERTAIN and at Weeks 12 and 24 of EXTEND according to each of: clinical disease activity index (CDAI) ≤2.8, CDAI ≤10.0, disease activity score (DAS)–28 CRP <2.6, DAS-28 CRP <3.2, and American College of Rheumatology (ACR)20/50/70 response criteria.

Results: A total of 168 patients entered EXTEND from ASCERTAIN, of whom 93 had been in the tocilizumab group (last tocilizumab dose 4 mg/kg in 37 patients and 8 mg/kg in 56 patients). After switch to sarilumab, response was achieved in an additional number of patients who were non-responders on tocilizumab at the end of ASCERTAIN (table 1). The reverse, response loss in tocilizumab responders, was infrequent. Patients who switched from tocilizumab 4 mg/kg or 8 mg/kg achieved similar response rates.

Last tocilizumab dose, mg/kg	Week in EXTEND	CDAI		DAS28-CRP		ACR20	ACR50	ACR70
		≤2.8	≤10	<2.6	<3.2			
		Non-responders at the end of ASCERTAIN with response in EXTEND (%) ^{a,b}						
4	12	3/27 ¹¹	7/18 ³⁹	8/23 ³⁵	8/18 ⁴⁴	3/5 (60)	8/19 ⁴²	7/25 ²⁸
	24	4/25 ¹⁶	7/16 ⁴⁴	9/22 ⁴¹	10/17 (59)	3/4 (75)	6/17 ³⁵	5/22 ²³
8	12	7/48 ¹⁵	9/31 ²⁹	13/36 ³⁶	8/21 ³⁸	2/11 ¹⁸	14/30 ⁴⁷	9/43 ²¹
	24	10/46 ²²	13/29 ⁴⁵	16/35 ⁴⁶	7/20 ³⁵	6/10 (60)	13/28 ⁴⁶	13/41 ³²
Responders at the end of ASCERTAIN with response in EXTEND (%) ^{a,b}								
4	12	8/89 (89)	15/83 (83)	11/110 (100)	16/160 (100)	28/31 (90)	16/17 (94)	10/11 (91)
	24	6/8 (75)	15/17 (88)	9/10 (90)	14/15 (93)	27/29 (93)	14/16 (88)	9/10 (90)
8	12	4/7 (57)	21/24 (88)	13/17 (76)	26/32 (81)	38/42 (90)	19/23 (83)	7/11 (64)
	24	5/7 (71)	20/24 (83)	14/18 (78)	28/33 (85)	39/43 (91)	19/24 (79)	9/12 (75)

^aresponder status according to measure listed in column heading; ^bsubjects with missing measurements are excluded from numerator and denominator

Conclusions: These results may indicate that clinical improvements can be attained in a relevant proportion of tocilizumab non-responders with switch to sarilumab, irrespective of previous tocilizumab dose, and the majority of patients responding to tocilizumab maintain response when switching to sarilumab.

Acknowledgements: Study sponsored by Sanofi and Regeneron Pharmaceuticals, Inc, who also funded medical writing support provided by Matt Lewis, Adelphi Group.

Disclosure of Interest: P. Verschueren Grant/research support from: Pfizer chair for early RA management KU Leuven, Consultant for: AbbVie, Bristol-Myers Squibb, Eli Lilly, Nordic Pharma, Merck Sharpe and Dohme, Pfizer, Roche, Sanofi and UCB, Paid instructor for: Pfizer, Sanofi, P. Emery Grant/research support from: AbbVie, Bristol-Myers Squibb, Pfizer, Merck Sharpe and Dohme and Roche, Consultant for: Bristol-Myers Squibb, AbbVie, Pfizer, Merck Sharpe and Dohme, Novartis, Roche and UCB, H. van Hoogstraten Shareholder of: Sanofi, Novartis, Employee of: Sanofi, Q. Dong Employee of: Sanofi, E. Mangan Shareholder of: Regeneron, Pfizer, Employee of: Regeneron, A. den Broeder Grant/research support from: Grant from Dutch Arthritis Association, and from CZ and MENZIS, two